Table 3 Terms significantly enriched in functional annotation and pathway analysis and genes present in the pathways potentially associated with eczema (FDR-adjusted P value; FDR = 0.05)
Term | FDR-adjusted P value | Â |
|---|---|---|
Polymorphism | 4.7 × 10−145 |  |
Sequence variant | 2.3 × 10−111 |  |
Alternative splicing | 6.8 × 10−74 |  |
Splice variant | 1.6 × 10−46 |  |
Phosphoprotein | 6.2 × 10−25 |  |
Protocadherin gamma | 1.8 × 10−16 | PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9, PCDHGB1, |
Disease mutation | 4.9 × 10−16 | PCDHGB2, PCDHGB3, PCDHGB4, PCDHGB5 |
Domain: cadherin 6 | 1.5 × 10−10 | FAT1, PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9, PCDHGB1, PCDHGB2, PCDHGB3, PCDHGB4, PCDHGB5 |
Cadherin, N-terminal | 3.6 × 10−10 | PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9, PCDHGB1, PCDHGB2, PCDHGB3, PCDHGB4, PCDHGB5 |
Pathways in cancer | 8.5 × 10−8 |  |
Membrane | 1.1 × 10−7 |  |
Regulation of actin cytoskeleton | 1.8 × 10−7 |  |
Long-term depression | 9.0 × 10−7 |  |
Calcium ion binding | 1.1 × 10−6 |  |
Plasma membrane | 2.2 × 10−6 |  |
Glycoprotein | 2.4 × 10−6 |  |
Gap junctiona | 2.6 × 10−6 | GNAS, GNAI2, GNAI3, GUCY1A3, MAP2K1, PDGFA,PRKG1 |
Cell-cell adhesion | 2.7 × 10−6 | CD164, CLDN5, CDSN,DAB1, FAT1, FGF6, PARD3, PTPRF, PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9, PCDHGB1,PCDHGB2,PCDHGB3, PCDHGB4, PCDHGB5 |
Homophilic cell adhesion | 6.1 × 10−6 |  |
Chemokine signaling pathway | 1.0 × 10−5 |  |
Focal adhesion | 1.3 × 10−5 |  |
Axon guidance | 1.3 × 10−5 | CLDN5, GNAI2, GNAI3, CSNK2B, MAGI2, MYL12B, PARD3 |
Tight junctiona | 1.6 × 10−5 | |
Biological adhesion | 1.7 × 10−5 |  |
Cell adhesion | 2.2 × 10−5 | AEBP1, CD164, CD36, CLDN5, COL11A2, COL20A1, CDSN, DAB1, FAT1, FGF6, IGSF11, LAMA4, LAMC1, NELL2, NTM, PARD3, PTPRF, PPFIA1, PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9, PCDHGB1, PCDHGB2, PCDHGB3, PCDHGB4, PCDHGB5 |
Coiled coil | 2.6 × 10−5 |  |
Melanogenesisa | 7.1 × 10−5 | GNAS, CREB3, GNAI2, GNAI3, MAP2K1, WNT10B |
Vascular smooth muscle contraction | 1.1 × 10−4 |  |
Chromosomal rearrangement | 2.6 × 10−4 |  |
Cardiac muscle contraction | 2.7 × 10−4 |  |
Intracellular signaling cascade | 4.5 × 10−4 |  |
Cell membrane | 4.7 × 10−4 |  |
Cell fraction | 4.8 × 10−4 |  |
Prostate cancer | 6.2 × 10−4 |  |
Ion binding | 6.8 × 10−4 |  |
Acetylation | 7.6 × 10−4 |  |
Signal | 8.3 × 10−4 |  |
Transmembrane | 1.0 × 10−3 |  |
Mutagenesis site | 1.1 × 10−3 |  |
Cation binding | 1.2 × 10−3 |  |
Lysine degradation | 1.4 × 10−3 |  |
Leukocyte trans endothelial migration | 1.5 × 10−3 |  |
Lysosome | 1.5 × 10−3 |  |
Transcription factor binding | 3.9 × 10−3 |  |
Melanomaa | 4.6 × 10−3 | E2F2, FGF6, MAP2K1, PDGFA |
Tumor suppressor | 5.0 × 10−3 |  |
Nucleotide binding | 5.0 × 10−3 |  |
Endocytosis | 7.0 × 10−3 |  |
Apoptosisa | 7.3 × 10−3 | CHP2, NTRK1, PPP3CA, RIPK1 |
Small cell lung cancer | 7.3 × 10−3 |  |
Nucleus | 1.1 × 10−2 |  |
Cell projection | 1.7 × 10−2 |  |
Positive regulation of cellular biosynthetic process | 4.4 × 10−2 |  |
Transcription co-activator activity | 4.9 × 10−2 |  |